Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of ianalumab in primary Sjögren's syndrome
NL-OMON50297Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing ianalumab dose arm(s) with placebo control (2 arms). Primary endpoint: Primary efficacy endpoint. Started Mar 2018; status: recruiting.
02
Drugs
ianalumab
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON50297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50297.